Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dinutuximab + Isotretinoin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dinutuximab | Unituxin | MOAB Ch14.18 | Unituxin (dinutuximab) is a monoclonal antibody that targets B4GALNT1 (GD2) and increases antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells (PMID: 26917818). Unituxin (dinutuximab) is FDA approved for pediatric high-risk neuroblastoma (FDA.gov). | |
Isotretinoin | Accutane Roche | Not Available |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06172296 | Phase III | Cyclophosphamide + Topotecan Cisplatin + Etoposide Dinutuximab + Irinotecan + Temozolomide Cisplatin + Dinutuximab + Etoposide Dinutuximab beta + Temozolomide Cisplatin + Cyclophosphamide + Dexrazoxane + Dinutuximab + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate Dinutuximab + Isotretinoin Carboplatin + Cyclophosphamide + Etoposide + Melphalan + Thiotepa Cisplatin + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Recruiting | USA | CAN | 0 |